53 related articles for article (PubMed ID: 21443270)
1. Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules.
Tolmachev V; Altai M; Sandström M; Perols A; Karlström AE; Boschetti F; Orlova A
Bioconjug Chem; 2011 May; 22(5):894-902. PubMed ID: 21443270
[TBL] [Abstract][Full Text] [Related]
2. First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [
Zhang M; Kang F; Xing T; Wang J; Ma T; Li G; Quan Z; Yang W; Chen X; Wang J
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1713-1724. PubMed ID: 38216779
[TBL] [Abstract][Full Text] [Related]
3. Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.
Rinne SS; Leitao CD; Mitran B; Bass TZ; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Jan; 9(1):655. PubMed ID: 30679757
[TBL] [Abstract][Full Text] [Related]
4. The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy.
Yin W; Xu T; Altai M; Oroujeni M; Zhang J; Vorobyeva A; Vorontsova O; Vtorushin SV; Tolmachev V; Gräslund T; Orlova A
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834389
[TBL] [Abstract][Full Text] [Related]
5. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.
Choi J; Vaidyanathan G; Koumarianou E; Kang CM; Zalutsky MR
Nucl Med Biol; 2018 Jan; 56():10-20. PubMed ID: 29031230
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging.
Chernomordik V; Hassan M; Lee SB; Zielinski R; Gandjbakhche A; Capala J
Mol Imaging; 2010 Aug; 9(4):192-200. PubMed ID: 20643022
[TBL] [Abstract][Full Text] [Related]
7. Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
Zhang J; Bodenko V; Larkina M; Bezverkhniaia E; Xu T; Liao Y; Abouzayed A; Plotnikov E; Tretyakova M; Yuldasheva F; Belousov MV; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
J Control Release; 2024 Jun; 370():468-478. PubMed ID: 38697314
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeling of HER2 specific Affibody(R) molecule with F-18.
Kiesewetter DO; Krämer-Marek G; Ma Y; Capala J
J Fluor Chem; 2008 Sep; 129(9):799-805. PubMed ID: 19727427
[TBL] [Abstract][Full Text] [Related]
9. Shorter Peptide Nucleic Acid Probes Improve Affibody-Mediated Peptide Nucleic Acid-Based Pretargeting.
Westerlund K; Oroujeni M; Gestin M; Clinton J; Hani Rosly A; Tano H; Vorobyeva A; Orlova A; Eriksson Karlström A; Tolmachev V
ACS Pharmacol Transl Sci; 2024 May; 7(5):1595-1611. PubMed ID: 38751640
[TBL] [Abstract][Full Text] [Related]
10. The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer.
Bragina OD; Deyev SM; Chernov VI; Tolmachev VM
Acta Naturae; 2022; 14(2):4-15. PubMed ID: 35923562
[TBL] [Abstract][Full Text] [Related]
11. Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide-Cysteine Chemistry.
Chigoho DM; Lecocq Q; Awad RM; Breckpot K; Devoogdt N; Keyaerts M; Caveliers V; Xavier C; Bridoux J
Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34201323
[TBL] [Abstract][Full Text] [Related]
12. Construction of homogeneous antibody-drug conjugates using site-selective protein chemistry.
Akkapeddi P; Azizi SA; Freedy AM; Cal PMSD; Gois PMP; Bernardes GJL
Chem Sci; 2016 May; 7(5):2954-2963. PubMed ID: 29997785
[TBL] [Abstract][Full Text] [Related]
13. Preliminary biological evaluation of
Lu C; Jiang Q; Hu M; Tan C; Yu H; Hua Z
Oncotarget; 2017 Aug; 8(31):51086-51095. PubMed ID: 28881632
[TBL] [Abstract][Full Text] [Related]
14. Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts.
Strand J; Honarvar H; Perols A; Orlova A; Selvaraju RK; Karlström AE; Tolmachev V
PLoS One; 2013; 8(8):e70028. PubMed ID: 23936372
[TBL] [Abstract][Full Text] [Related]
15. Assessment of an elastin binding molecule for PET imaging of atherosclerotic plaques.
Fischer CR; Müller A; Bochsler B; Rancic Z; Kaufmann P; Schibli R; Ametamey SM
Am J Nucl Med Mol Imaging; 2013; 3(4):326-35. PubMed ID: 23901358
[TBL] [Abstract][Full Text] [Related]
16. Radiofluorination using aluminum-fluoride (Al18F).
McBride WJ; Sharkey RM; Goldenberg DM
EJNMMI Res; 2013 May; 3(1):36. PubMed ID: 23651690
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography (PET) imaging with (18)F-based radiotracers.
Alauddin MM
Am J Nucl Med Mol Imaging; 2012; 2(1):55-76. PubMed ID: 23133802
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
Malmberg J; Perols A; Varasteh Z; Altai M; Braun A; Sandström M; Garske U; Tolmachev V; Orlova A; Karlström AE
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):481-92. PubMed ID: 22322933
[TBL] [Abstract][Full Text] [Related]
19. The radiolabeling of proteins by the [18F]AlF method.
McBride WJ; D'Souza CA; Sharkey RM; Goldenberg DM
Appl Radiat Isot; 2012 Jan; 70(1):200-4. PubMed ID: 21890371
[TBL] [Abstract][Full Text] [Related]
20. Maleimido-functionalized NOTA derivatives as bifunctional chelators for site-specific radiolabeling.
Förster C; Schubert M; Pietzsch HJ; Steinbach J
Molecules; 2011 Jun; 16(6):5228-40. PubMed ID: 21697778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
